On November 2, 2020, the SEC filed an emergency action in the United States District Court for the Eastern District of New York against a company that has been charged with fraud in connection with an ongoing drug development program.  According to the SEC's complaint, filed in the U.S. District Court for the Eastern District of New York, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) was not approved for the treatment of Parkinson's disease psychosis and Alzheimer's disease psychosis.  The SEC's complaint, filed in the SEC's Eastern District of New York, alleges that ACADIA failed to adequately assess the safety and efficacy of its new drug, pimavanserin.  The complaint further alleges that ACADIA failed to adequately evaluate the safety and efficacy of its new drug.  The SEC's complaint charges ACADIA with violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, ACADIA has agreed to the entry of a final judgment that permanently enjoins it from violating the antifraud provisions of the federal securities laws and orders it to pay a civil penalty of $100,000.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Marc Goodman and Kelly L. Gibson of the Boston Regional Office.  The litigation will be led by Ms. Gibson and Ms. Gibson.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Eastern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.